GPRC5D and congenital rubella syndrome: Of nine patients who had received anti-BCMA CAR T-cell therapy previously, CRS occurred in eight (89%) patients after anti-GPRC5D CAR T-cell infusion, with six having lower grade of CRS than anti-BCMA CAR T cells (Table 2).